CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma

Exclusion Criteria

• •1. Pregnant or lactating female subjects.
• •2. Pregnant or lactating female subjects.
• •3. Known positive test result for human immunodeficiency virus (HIV) oracquired immune deficiency syndrome (AIDS).
• •4. Active infection or uncontrollable infection.
• •5. Known to have active or uncontrolled autoimmune diseases, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, etc. .
• •6. Having a history of any mental illness, including dementia, altered mental status, which may affect informed consent and the understanding of the subject by the relevant questionnaire.
• •7. Have a serious uncontrollable illness that may affect the subject receiving treatment for this study.
• •8. Subjects with other malignant tumors within the past 2 years, except basal or squamous skin cancer, superficial bladder cancer, and breast cancer in situ, have been completely cured and do not need follow-up treatment.
• •9. Subjects who are using systemic steroids or steroid inhalers for treatment.
• •10. Use of anti-CD70 therapy or cell therapy within the previous 3 months.
• •11. Immunotherapy, targeted drug therapy or chemotherapy within 5 drug half-lives within 2 weeks before cell infusion.
• •12. Subjects allergic to immunotherapy or related drugs.
• •13. Patients with leptomeningeal metastasis or central nervous system metastasis, and definite central nervous system underlying diseases with significant symptoms in the past 6 months.
• •14. Subjects with NYHA heart failure class ≥2 or hypertension uncontrolled by standard therapy requiring special treatment, previous history of myocarditis, or myocardial infarction within 6 months.
• •15. Earnestly received or organ transplantation or preparing to receive organ transplants.
• •16. Other investigators deem it unsuitable to participate in the study.